Lamotrigine
- Generic Name
- Lamotrigine
- Brand Names
- Lamictal
- Drug Type
- Small Molecule
- Chemical Formula
- C9H7Cl2N5
- CAS Number
- 84057-84-1
- Unique Ingredient Identifier
- U3H27498KS
- Background
Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 cou...
- Indication
Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome.
...
- Associated Conditions
- Bipolar 1 Disorder, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Seizures, Generalized
- Associated Therapies
- Conversion to monotherapy
Cognitive Effects of Treatment of Interictal Discharges
- First Posted Date
- 2009-06-09
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT00916149
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00907985
- Locations
- 🇩🇪
GSK Investigational Site, Goettingen, Niedersachsen, Germany
Lamotrigine Augmentation in Resistant Depression
- Conditions
- Interventions
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2009-05-13
- Target Recruit Count
- 138
- Registration Number
- NCT00901407
- Locations
- 🇺🇸
LSUHSC- New Orleans, New Orleans, Louisiana, United States
Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT00834561
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT00835263
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 301
- Registration Number
- NCT00723450
- Locations
- 🇺🇸
GSK Investigational Site, Seattle, Washington, United States
Lamotrigine Therapy in Geriatric Bipolar Depression
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 69
- Registration Number
- NCT00720473
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
Efficacy and Safety of Antidepressant Augmentation With Lamotrigine
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-04-09
- Target Recruit Count
- 34
- Registration Number
- NCT00652171
Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder
- Conditions
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2008-03-12
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT00634062
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
AED/Statin Interaction Study
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 119
- Registration Number
- NCT00627575
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.